Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long
On January 26, 2016 at 2:00 pm, GeneCentric’s Hawazin Faruki will speak at the Personalized Medicine World Conference (PMWC) 2016 Silicon Valley on “Genomic Tumor Profiling – Advancing Beyond Gene Mutations.” PMWC 2016 SV, co-hosted with Stanford Health Care and UCSF on January 24-27, will gather 1200 multidisciplinary attendees and key stakeholders from the business, […]
On May 5, 2015, GeneCentric will present at the Southeast Investor & Venture Philanthropy Oncology Summit 2015. The Summit features more than 30 of the Southeast’s top private oncology companies. Attendees come from small and large oncology-focused companies, venture philanthropies and investment groups.
GeneCentric is one of only 13 companies selected to participate at this year’s CED Life Science Conference Showcase. Dr. Myla Lai-Goldman, CEO of GeneCentric, will be presenting an overview of the company’s science and business model. The presentation will take place on Tuesday, March 3rd at 4:10pm at the Convention Center in Raleigh, North Carolina.
On November 15, 2014, at the annual Association of Molecular Pathology meeting in Maryland just outside Washington DC, GeneCentric presented a validation study of its Lung Cancer Gene Expression Subtyping Panel (LSP) using RT-qPCR of formalin fixed paraffin embedded samples. The LSP gene signature has been shown to be a robust method for classifying lung […]